An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Indi… (NCT03882918) | Clinical Trial Compass
TerminatedPhase 3
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
Stopped: Company decision
United States141 participantsStarted 2019-01-31
Plain-language summary
This open-label study (OV101-18-002) will evaluate the long-term (52 weeks) safety of OV101 in subjects with AS and provide additional OV101 treatment to those subjects who completed Study OV101-15-001 (NCT02996305). Subjects with AS who completed the pharmacokinetic Study OV101-16-001 (NCT03109756) will also be permitted to participate, provided they meet all entry criteria.
Who can participate
Age range13 Years – 49 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Has completed the OV101-15-001 or OV101-16-001 study up to the EOS.
✓. Is male or female and 13 to 49 years old (inclusive) at the time of inclusion in the OV101-15-001 or OV101-16-001 study.
✓. Has a previous diagnosis of AS with molecular confirmation from the OV101-15-001 or OV101-16-001 study.
✓. Has an LAR/caregiver capable of providing informed consent and able to attend all scheduled study visits, oversee the administration of study drug, and provide feedback regarding the subject's symptoms and performance as described in the protocol.
✓. Provides assent to the protocol (to the extent possible and in accordance with local institutional review board (IRB) and regulatory requirements) and has an LAR/caregiver who will provide written informed consent. Subjects providing assent must do so at the same visit as LAR/caregiver written informed consent is provided.
✓. Can swallow study drug capsules or ingest the contents of study drug capsules after sprinkling the capsule contents onto 1 spoon of applesauce or low-fat yogurt.
✓. Is currently receiving a stable dose of concomitant medications such as anti-epileptic medication, gabapentin, clonidine, trazadone, melatonin, and special diets for at least 4 weeks prior to Baseline.
✓
What they're measuring
1
Incidence of Participants Experiencing Adverse Events in Active Treatment Group
. Agrees to remain sexually abstinent from the first day of screening until 30 days after the last dose of study treatment.
Exclusion criteria
✕. Discontinued from the OV101-15-001 or OV101-16-001 study due to safety reasons causally related to OV101.
✕. Has a concomitant disease (eg, gastrointestinal, renal, hepatic, endocrine, respiratory, or cardiovascular system disease) or condition or any clinically significant finding at Screening that could interfere with the conduct of the study or that would pose an unacceptable risk to the subject in this study.
✕. Has poorly controlled seizures defined as \> 3 seizures lasting \< 3 minutes per week or \> 1 seizure episode lasting more than 3 minutes per week or as per medical monitor judgment.
✕. Has clinically significant clinical laboratory abnormalities or vital signs at the time of screening (eg, alanine aminotransferase or aspartate aminotransferase \> 2.5 × upper limit of normal; total bilirubin or creatinine \> 1.5 × upper limit of normal). Retesting of clinical laboratory parameters may be allowed after consultation with the medical monitor or designee.
✕. Current use of benzodiazepines, zolpidem, zaleplon, zopiclone, eszopiclone, barbiturates, or ramelteon for sleep within the 4 weeks prior to Day 1. Benzodiazepines administered for situational anxiety related to occasional procedures or events are permitted.
✕. Has a history of suicidal behavior or is considered by the investigator to be at increased risk of suicide.
✕. Has any condition or circumstance that, in the opinion of the investigator, makes the subject unsuitable for enrollment.
✕. Has enrolled in any clinical trial or used any investigational agent or device, or has participated in any investigational procedure, within the 30 days before screening or does so concurrently with this study.